AMAZE 1: Amycretin Phase 3 trial (NCT07339423)
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Recruiting
- Enrolment
- 1,150
- estimated
- Start
- 24 Feb 2026 (actual)
- Primary completion
- 26 Jun 2029 (estimated)
- Sponsor
- Novo Nordisk A/S
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| NNC0487-0111 | Experimental | Drug: NNC0487-0111 | Participants will be randomized to receive 1 out of 4 different dose levels subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity. |
| Placebo | Placebo comparator | Drug: Placebo (matched to NNC0487-0111) | Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Relative change in body weight | From baseline (week 0) to week 84 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change in waist circumference | From baseline (week 0) to week 84 and week 136 |
| Change in systolic blood pressure (SBP) | From baseline (week 0) to week 84 and week 136 |
| Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function score | From baseline (week 0) to week 84 and week 136 |
| Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score | From baseline (week 0) to week 84 and week 136 |
| Change in body weight | From baseline (week 0) to week 84 and week 136 |
| Change in body mass index (BMI) | From baseline (week 0) to week 84 and week 136 |
| Change in IWQOL-Lite-CT physical composite score | From baseline (week 0) to week 84 and week 136 |
| Change in IWQOL-Lite-CT psychosocial composite score | From baseline (week 0) to week 84 and week 136 |
| Change in IWQOL-Lite-CT total score | From baseline (week 0) to week 84 and week 136 |
| Change in glycated haemoglobin (HbA1c) | From baseline (week 0) to week 84 and week 136 |
| Change in fasting plasma glucose (FPG) | From baseline (week 0) to week 84 and week 136 |
| Ratio to baseline: change in fasting insulin | From baseline (week 0) to week 84 and week 136 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.